Our second Modulating the Tumour Microenvironment conference presents innovations for enhancing the immune anti-tumour response and overcoming inhibitory factors. It is becoming clear that many immunosuppressive mechanisms are at work. The checkpoint inhibitors are not living up to expectations, and for these and other antagonists to be effective, it is necessary to control Tregs and manipulate myeloid-derived and other suppressor cells in the tumour microenvironment (TME). The leaders in the field are also paying attention to the role of cytokines and the importance of Fc-engagement for effective targeting.
Coverage will include, but is not limited to:
- Novel approaches to target the tumour stroma
- Targeting immune checkpoint inhibitors (CPIs) and antagonists (eg PD-1, CTLA-4): overcoming limitations
- Targeting regulatory T cells (Tregs) to manipulate the tumour vasculature and enhance T-cell tumour targeting
- Targeting myeloid-derived and other suppressor cells to overcome inhibitory mechanisms
- Focus on Fc engagement for effective targeting: Fc-optimization of immuno-modulatory antibodies; targeting antibody checkpoints FcγRIIb
- Bispecific agonists with checkpoint blockade
- Measures to enhance efficacy of agonistic immuno-stimulatory antibodies
- Design of therapeutics to ensure activity in the TME and not in the periphery
- Innovative approaches with cytokines: mechanisms of action and benefits; impact of the cytokine environment on the immuno-suppressive cell populations infiltrating tumours
- Focus on isotype selection: IgA, IgG1, IgG2
- Impact of oncolytic viruses and vector vaccines on immune modulation
- Targeting cancer-specific glycoforms and glyco-immune checkpoints
* The program is subject to change without notice, due to unforeseen reason.